SecBot SecBot
8-K ·Filed Feb 25, 2026

LMAT

LEMAITRE VASCULAR INC
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001193125-26-071954
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of accelerating top-line growth, expanding margins, strong guidance, and increased capital returns suggests robust operational execution. Traders should monitor whether the stock re-rates on improved profitability expectations and whether Q1 2026 results meet the high end of guidance ($67.6 million revenue).

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$113.43
T+0 close · Feb 25, 2026 · via day close
Latest settled
−12.26%
T+60 · $99.52
Vs SPY
−20.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $113.43entry
  2. T+1 · 9mo ago −4.85%α −4.39% · $107.93
  3. T+5 · 9mo ago −6.63%α −5.50% · $105.91
  4. T+20 · 8mo ago −2.73%α +3.67% · $110.33
  5. T+60 · 6mo ago −12.26%α −20.01% · $99.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

LeMaitre Vascular (LMAT) reported strong Q4 2025 results with revenue of $64.5 million (+16% YoY) and diluted EPS of $0.68 (+39% YoY), driven by international growth and margin expansion. The company raised its quarterly dividend by 25% to $0.25/share and authorized a $100 million share repurchase program. Full-year 2026 guidance calls for $280 million in sales (+12%) and operating income of $77.8 million (+21% adjusted), signaling continued profitability growth.

Key Financial Metrics

Revenue
$64.5M
+15.7% YoY
EPS
$0.68
Guidance
$276mm - $284mm
raised
Gross Margin
71.7%

Key Facts

  • Q4 2025 revenue: $64.5 million (+16% YoY, +15% organic)
  • Q4 2025 diluted EPS: $0.68 (+39% YoY)
  • Gross margin expanded 240 bps to 71.7%
  • Operating income: $18.8 million (+47% YoY)
  • 2026 full-year sales guidance: $276–284 million (midpoint $280 million, +12%)
  • 2026 full-year operating income guidance: $75.0–80.7 million (midpoint $77.8 million, +15% GAAP, +21% adjusted)
  • Quarterly dividend increased 25% to $0.25/share
  • Authorized $100 million share repurchase program

Financial Impact

Revenue up $8.7 million YoY, operating income up $5.9 million YoY, with $100 million in capital returned via buyback authorization

revenueepsgross_marginoperating_incomedividendshare_count

Segment Breakdown

SegmentGrowth
Grafts+27.0%
Valvulotomes+20.0%
Carotid Shunts+18.0%

Risk Factors

  • Forward-looking guidance is subject to risks including international market volatility and supply chain disruptions
  • Increased share count from convertible notes could dilute EPS if not offset by buybacks
  • Valuation could become stretched if execution falters

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-071954
Document: d23187d8k.htm0001193125-26-071954
Document: 0001193125-26-071954-index-headers.html0001193125-26-071954
Document: 0001193125-26-071954-index.html0001193125-26-071954
Document: 0001193125-26-071954.txt0001193125-26-071954

Track record

14 reports on LMAT

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.08% at T+20 after the May 7, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 4, 202612d ago 8-K Bearish 6/10 Entry $83.49 to $77.65 Now $77.01 +7.76% ▲ +6.99% +10.29% vs SPY
  2. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $80.60 to $79.02 Now $77.01 −4.45% ▼ −1.96% −1.37% vs SPY
  3. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $80.82 to $84.45 Now $77.01 −4.71% ▲ +4.49% +4.40% vs SPY
  4. Aug 27, 202611w ago Press Release Neutral 2/10 Entry $80.45 to $80.67 Now $77.01 −4.28% ▲ +0.27% +0.16% vs SPY
  5. Jul 14, 202617w ago Press Release Neutral 1/10 Entry $99.79 Now $77.01 −22.83% No price data
  6. May 7, 202627w ago Insider Cluster Bearish 4/10 Entry $107.91 to $98.17 Now $77.01 +28.63% ▲ +9.03% +10.53% vs SPY
  7. May 7, 202627w ago Insider Cluster Neutral 2/10 Entry $107.91 to $98.17 Now $77.01 −28.63% ▼ −9.03% −10.53% vs SPY
  8. May 7, 202627w ago Insider Cluster Neutral 3/10 Entry $107.91 to $98.17 Now $77.01 −28.63% ▼ −9.03% −10.53% vs SPY
  9. May 5, 202627w ago 8-K Bullish 7/10 Entry $110.22 to $97.22 Now $77.01 −30.13% ▼ −11.79% −12.93% vs SPY
  10. Apr 14, 202630w ago DEFA14A Neutral 3/10 Entry $117.39 to $111.90 Now $77.01 −34.40% ▼ −4.68% −6.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026